Yonghua Liu

State Key Laboratory Of Bioactive Substances And Functions Of Natural Medicines, Peking Union Medical College And Chinese Academy Of Medical Sciences
Beijing, 100050, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Linking intestinal distribution to pharmacological mechanism: Berberine prevents and treats colorectal cancer by targeting SIGMAR1.

Linking intestinal distribution to pharmacological mechanism: Berberine prevents and treats colorectal cancer by targeting SIGMAR1.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: February 15, 2026

Design, synthesis and activity evaluation of benzene sulfonamide derivatives as novel androgen receptor antagonist.

Design, synthesis and activity evaluation of benzene sulfonamide derivatives as novel androgen receptor antagonist.

Journal: European journal of medicinal chemistry

Published: April 02, 2025

Evolution of 8-esterified cycloberberines as a novel class of antibacterial agents against MDR gram-positive strains by targeting DNA polymerase IIIC.

Evolution of 8-esterified cycloberberines as a novel class of antibacterial agents against MDR gram-positive strains by targeting DNA polymerase IIIC.

Journal: Bioorganic chemistry

Published: February 25, 2025

Pyrylium derivatives as outer membrane permeabilizers against MDR gram-negative bacteria via multi-target mode of action.

Pyrylium derivatives as outer membrane permeabilizers against MDR gram-negative bacteria via multi-target mode of action.

Journal: European journal of medicinal chemistry

Published: January 02, 2025

Synthesis and evolution of 16-membered macrolide carrimycin derivatives as a novel class of anti-HCoV-OC43 agents targeting viral FSE RNA.

Synthesis and evolution of 16-membered macrolide carrimycin derivatives as a novel class of anti-HCoV-OC43 agents targeting viral FSE RNA.

Journal: European journal of medicinal chemistry

Published: December 23, 2024

Novel pyridazinone derivatives bind to KSRP: Synthesis, anti-tumor biological evaluations and modelling insights.

Novel pyridazinone derivatives bind to KSRP: Synthesis, anti-tumor biological evaluations and modelling insights.

Journal: European journal of medicinal chemistry

Published: July 30, 2024

Structure-activity relationship study of new carbazole sulfonamide derivatives as anticancer agents with dual-target mechanism.

Structure-activity relationship study of new carbazole sulfonamide derivatives as anticancer agents with dual-target mechanism.

Journal: European journal of medicinal chemistry

Published: March 25, 2024

Erratum: Author correction to 'Discovery and identification of EIF2AK2 as a direct key target of berberine for anti-inflammatory effects' [Acta Pharmaceutica Sinica B 13 (2023) 2138-2151].

Erratum: Author correction to 'Discovery and identification of EIF2AK2 as a direct key target of berberine for anti-inflammatory effects' [Acta Pharmaceutica Sinica B 13 (2023) 2138-2151].

Journal: Acta pharmaceutica Sinica. B

Published: March 15, 2024

Design, synthesis and biological evaluation of biaryl amide derivatives against SARS-CoV-2 with dual-target mechanism.

Design, synthesis and biological evaluation of biaryl amide derivatives against SARS-CoV-2 with dual-target mechanism.

Journal: European journal of medicinal chemistry

Published: September 07, 2023

Evolution and development of potent monobactam sulfonate candidate IMBZ18g as a dual inhibitor against MDR Gram-negative bacteria producing ESBLs.

Evolution and development of potent monobactam sulfonate candidate IMBZ18g as a dual inhibitor against MDR Gram-negative bacteria producing ESBLs.

Journal: Acta pharmaceutica Sinica. B

Published: November 22, 2022

Discovery and identification of EIF2AK2 as a direct key target of berberine for anti-inflammatory effects.

Discovery and identification of EIF2AK2 as a direct key target of berberine for anti-inflammatory effects.

Journal: Acta pharmaceutica Sinica. B

Published: September 06, 2022

Discovery and development of palmatine analogues as anti-NASH agents by activating farnesoid X receptor (FXR).

Discovery and development of palmatine analogues as anti-NASH agents by activating farnesoid X receptor (FXR).

Journal: European journal of medicinal chemistry

Published: July 26, 2022

Showing 1-12 of 18

Last Updated: 09/26/2026